University of Rhode Island
West Virginia University
University of Nebraska Medical Center
The Ph.D. Program for Neural Regenerative Medicine, TMU
Northern Michigan University
Tennessee State University
Low Molecular Weight Cyclin E Deregulates Dna Replication And Damage Repair To Promote Genomic Instability In Breast Cancer,
2023
The Texas Medical Center Library
Low Molecular Weight Cyclin E Deregulates Dna Replication And Damage Repair To Promote Genomic Instability In Breast Cancer, Mi Li
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access)
Low molecular weight cyclin E (LMW-E) are oncogenic forms of cyclin E that are post translationally generated by neutrophil elastase (NE) mediated cleavage of the 50 KDa full-length cyclin E1 (FL-cycE, encoded by CCNE1gene). The resultant N-terminus deleted (40 amino acids) form of LMW-E is detected in breast cancer cells and tumor tissues, but not in normal mammary epithelial cells or adjacent normal tissues. Unlike FL-cycE, LMW-E drives mammary epithelial cell transformation in human cells and spontaneous mammary tumor formation in transgenic mouse models, but the oncogenic mechanisms of LMW-E and its unique function(s) independent of FL-cycE are not …
Predicting If Lung Cancer Will Relapse—The Role Of Neutrophil/Lymphocyte Ratio,
2023
Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA
Predicting If Lung Cancer Will Relapse—The Role Of Neutrophil/Lymphocyte Ratio, Abigail Chan, Søren Bentzen, Amit Rout, Kenneth Miller
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Baseline neutrophil/lymphocyte ratio (NLR), a surrogate marker for systemic inflammation and immunosuppression, is a well-studied prognostic marker in nonsmall cell lung cancer (NSCLC). This study tests if interim NLR is prognostic in NSCLC patients in remission. Methods: This single-center, retrospective cohort study analyzed 131 NSCLC patients treated from 2010 to 2015 who achieved complete remission. NLR was calculated at baseline and from the first available blood sample during remission. Kaplan–Meier estimates of overall survival (OS) and time to recurrence were compared using the log-rank test for trend. Multivariable analysis was conducted using the Cox proportional hazards model. Results: Of …
Impact Of Pre-Transplant Induction Therapy On Outcomes Of Patients Who Undergo Autologous Stem Cell Transplantation For Mantle Cell Lymphoma In First Complete Remission,
2023
Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA
Impact Of Pre-Transplant Induction Therapy On Outcomes Of Patients Who Undergo Autologous Stem Cell Transplantation For Mantle Cell Lymphoma In First Complete Remission, Omar Albanyan, Samer Alkassis, Seongho Kim, Andrew Kin, Asif Alavi, Lois Ayash, Voravit Ratanatharathorn, Dipenkumar Modi, Joseph P. Uberti, Abhinav Deol
Hematology/Oncology and Stem Cell Therapy
Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials. We retrospectively evaluated 66 patients diagnosed with mantle cell lymphoma who achieved first complete response after induction chemotherapy followed by autologous stem cell transplant. Treatment groups were divided into lowintensity versus high-intensity regimens. Our data showed the intensity of induction regimen does not impact posttransplant outcomes of mantle cell lymphoma who underwent autologous stem cell transplant in first complete response.
Promising Effect Of Pdl1 Inhibitors In The Front-Line Management Of Primary Aggressive Central Nervous System Lymphoma: A Case Report,
2023
Department of Hematology, Kuwait Cancer Control Center, Kuwait
Promising Effect Of Pdl1 Inhibitors In The Front-Line Management Of Primary Aggressive Central Nervous System Lymphoma: A Case Report, Rasha El-Tawab, Abdulaziz Hamada, Rehab Elhagracy, Karen Pinto, Salem Alshemmari
Hematology/Oncology and Stem Cell Therapy
Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that involves the central nervous system. The standard treatment involves chemotherapy with high-dose methotrexate. To the best of our knowledge, this is the first reported case of employing checkpoint inhibitor, nivolumab, alone to treat a patient with PCNSL who could not tolerate the induction therapy. In aggressive cases of PCNSL where chemotherapy may become futile, stand-alone checkpoint inhibitors should be considered as the front-line treatment protocol.
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma,
2023
Department of Internal Medicine, Division Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA
Predictors And Management Of Relapse To Axicabtagene Ciloleucel In Patients With Aggressive B-Cell Lymphoma, Jose Vicente Forero-Forero, Paula A. Lengerke-Diaz, Eider Moreno-Cortes, Megan Melody, Zaid Abdel Rahman, Allison C. Rosenthal, Mohamed A. Kharfan-Dabaja, Januario E. Castro
Hematology/Oncology and Stem Cell Therapy
Objective/background: Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. Methods: We performed a retrospective study of aNHL patients treated with axicabtagene ciloleucel (axi-cel) at two Mayo Clinic centers between 2018 and 2020. We evaluated predictive factors, toxicities, and responses to salvage regimens after CAR T-cell therapy. Results: Thirty-four patients received axi-cel with a median length of hospitalization of 14 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome of any grade occurred in 91% and 41% of patients, respectively. …
Immune Checkpoint Inhibitor-Induced Pneumonitis: Incidence, Clinical Characteristics, And Outcomes,
2023
Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI, USA
Immune Checkpoint Inhibitor-Induced Pneumonitis: Incidence, Clinical Characteristics, And Outcomes, Harsha Banavasi, Seongho Kim, Samer Alkassis, Asil Daoud, Amir Laktineh, Misako Nagasaka, Ammar Sukari, Ayman O. Soubani
Hematology/Oncology and Stem Cell Therapy
Background: Immune checkpoint inhibitors (ICIs) are the newest class of anticancer drugs. Pneumonitis is increasingly being recognized as a potential complication of these agents. Methods: We conducted a retrospective study of patients who received ICIs at a comprehensive cancer center. We collected data on demographics, type of malignancy, type of ICI agent, incidence of pneumonitis up to 6 weeks after receiving ICI agent, clinical characteristics, and risk factors for overall survival in patients who develop pneumonitis. Results: A total of 654 patients received ICIs during the study period. The most common type of cancer for which ICI was given was …
Changes In Heme Levels During Acute Vaso-Occlusive Crisis In Sickle Cell Anemia,
2023
Hematology and Hemotherapy Foundation from Amazonas State (HEMOAM), Manaus, AM, Brazil
Changes In Heme Levels During Acute Vaso-Occlusive Crisis In Sickle Cell Anemia, Evilazio Cunha Cardoso, Pedro Vieira Silva-Neto, Bidossessi Wilfried Hounkpe, Francine Chenou, Cintia Cristina Mateus Xerez Albuquerque, Nadja Pinto Garcia, Alexander Leonardo Silva-Junior, Adriana Malheiro, Purim Cesar, Franciele De Lima, Erich V. De Paula, Nelson Abrahim Fraiji
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Sickle cell anemia (SCA) is associated with increased levels of extracellular heme, which is a key mediator of inflammation in this condition. Despite abundant evidence supporting this concept in cell and animal models, few studies addressed the association between heme levels and the development and severity of acute vaso-occlusive crises (VOC) in humans. Methods: A cross-sectional study was conducted in patients with acute VOC. Total extracellular heme levels were measured in both plasma and serum at admission and after convalescence, and correlated with other clinical and laboratory markers of SCA severity. Results: A total of 28 episodes of VOC …
Diagnosis And Treatment Of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Systematic Literature Review,
2023
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Diagnosis And Treatment Of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Systematic Literature Review, Dunya Yunus Alsomali, Nasir Bakshi, Mohamed Kharfan-Dabaja, Riad El Fakih, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Objectives: The aim of this systematic review is to investigate different diagnostic methods and the available treatment options for subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Methods: We searched PubMed, Web of Science, SCOPUS, EBSCO, and CINAHL Plus for published case reports of SPTCL. From each record, we extracted data of the diagnostic methods, immunohistochemical profile, clinical characteristics, and the treatment approaches provided. Data were summarized and narratively synthesized to highlight the various diagnostic methods and treatment options of SPTCL. Results: Our literature search yielded 1293 unique citations. Following screening, nine articles reporting a total of 15 cases were included in this …
Cross Fire: Daratumumab-Based Therapies Are Standard Of Care In Newly Diagnosed Multiple Myeloma,
2023
Multiple Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cross Fire: Daratumumab-Based Therapies Are Standard Of Care In Newly Diagnosed Multiple Myeloma, Neha Korde, Saad Z. Usmani
Hematology/Oncology and Stem Cell Therapy
There is no abstract.
Current Status And Future Perspectives On The Internet Of Things In Oncology,
2023
Department of Medicine, Houston Methodist Hospital, Houston, TX, USA
Current Status And Future Perspectives On The Internet Of Things In Oncology, Ibrahim N. Muhsen, Omar W. Rasheed, Eiad A. Habib, Rakan K. Alsaad, Mohannad K. Maghrabi, Md A. Rahman, Douglas Sicker, William A. Wood, Muhammad S. Beg, Anthony D. Sung, Shahrukh K. Hashmi
Hematology/Oncology and Stem Cell Therapy
The Internet of Things (IoT) has penetrated many aspects of everyday human life. The use of IoT in healthcare has been expanding over the past few years. In this review, we highlighted the current applications of IoT in the medical literature, along with the challenges and opportunities. IoT use mainly involves sensors and wearables, with potential applications in improving the quality of life, personal health monitoring, and diagnosis of diseases. Our literature review highlights that the current main application studied in the literature is physical activity tracking. In addition, we discuss the current technologies that would help IoT-enabled devices achieve …
Efficacy And Safety Of Recombinant Thrombomodulin For The Prophylaxis Of Veno-Occlusive Complication In Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review And Meta-Analysis,
2023
North Alabama Medical Center, Florence, AL, USA
Efficacy And Safety Of Recombinant Thrombomodulin For The Prophylaxis Of Veno-Occlusive Complication In Allogeneiccit Hematopoietic Stem Cell Transplantation: A Systematic Review And Meta-Analysis, Richi Kashyap, Faiz Anwer, Muhammad Areeb Iqbal, Farhan Khalid, Anam Khan, Muhammad Ashar Ali, Muhammad Yasir Anwar, Anamika Chaudhary, Ali Jaan
Hematology/Oncology and Stem Cell Therapy
Background: Hepatic veno-occlusive disease (VOD), also termed as sinusoidal obstruction syndrome (SOS), is a lethal complication after hematopoietic stem cell transplantation (HSCT). Various factors put patients undergoing allogeneic HSCT at an increased risk for VOD. Thrombomodulin (TM) is an important factor which has a wide range of effects, including anticoagulant, anti-inflammatory, angiogenic, and protective effect, on endothelial cells. It plays a role in preventing excessive coagulation and thrombosis by binding with thrombin and inhibiting the coagulation cascade. There are a limited number of options for the prevention of this fatal complication. Recombinant thrombomodulin (rTM), an endothelial anticoagulant co-factor,
as prophylactic …
Strange Bedfellows: Npm1 Mutations In Acute Promyelocytic Leukemia,
2023
Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland
Strange Bedfellows: Npm1 Mutations In Acute Promyelocytic Leukemia, Stephen E. Langabeer
Hematology/Oncology and Stem Cell Therapy
No Abstract for this article type
Outcome Of Myeloma Patients With Covid-19 On Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe Covid-19?,
2023
Department of Adult Hematology and Bone Marrow Transplantation, King Fahad Medical City, Riyadh, Saudi Arabia
Outcome Of Myeloma Patients With Covid-19 On Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe Covid-19?, Imran K. Tailor, Nawal F. Alshehry, Syed Z. Zaidi, Mohammed A. Marei, Ibraheem H. Motabi, Mansour Alfayez, Syed Y. Altaf
Hematology/Oncology and Stem Cell Therapy
No abstract for this article type.
Use Of Checkpoint Inhibitors In Gray Zone Lymphoma,
2023
Universidade Federal do Ceara´, Fortaleza, Ceara´, Brazil
Use Of Checkpoint Inhibitors In Gray Zone Lymphoma, Yensy Mariana Zelaya Rosales, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Fernando Ricardo Fernandes Paz, Naiana Castelo Branco Campos, Joa˜O Paulo De Vasconcelos Leita˜O, Francisco Da´Rio Rocha Filho, Ricardo Vale Albino Oliveira Filho, Rome´Lia Pinheiro Gonc¸Alves Lemes, Fernando Barroso Duarte
Hematology/Oncology and Stem Cell Therapy
Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. This is a case report of a difficult diagnosis and describes the most current treatment using checkpoint inhibitors, through the review of the clinical record of a patient diagnosed with gray area …
High Expression Of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes In Non-M3 Acute Myeloid Leukemia Patients,
2023
Department of Hematology, School of Medicine, Tarbiat Modares University (TMU), Tehran, Iran.
High Expression Of Long Noncoding Rna Norad Is Associated With Poor Clinical Outcomes In Non-M3 Acute Myeloid Leukemia Patients, Mohammad Masoud Eslami, Mina Soufizomorrod, Mohammad Ahmadvand
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Dysregulation of long noncoding RNA NORAD has been identified in human solid tumors. However, the expression profile of NORAD and its clinical implications in acute myeloid leukemia (AML) is unclear. The current study aimed to explore the NORAD expression status and its clinical significance in non-M3 AML patients. Methods: NORAD expression was evaluated in 60 de novo non-M3 AML patients and 49 healthy individuals using quantitative reverse transcription–polymerase chain reaction method. The correlation between NORAD transcription levels and clinicopathologic characteristics was statistically studied. Results: Compared with the healthy controls, NORAD was consistently higher in non-M3 AML patients (p = …
Prophylactic Pretransplant Ganciclovir To Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation,
2023
Section of Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA
Prophylactic Pretransplant Ganciclovir To Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation, Daniel R. Reed, Gina R. Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G. Williams, Kathlene Degregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan, Leonid Volodin, Gerald R. Donowitz, Tamila L. Kindwall-Keller, Karen K. Ballen
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Cytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60–70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure. Methods: Ganciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT. CMV DNA was monitored weekly until at least Day 100 posttransplant. Results: A total of 109 consecutive patients were treated, median age 57 (range 20–73) years. Of these, 36 (33%) patients had a CMV reactivation within the …
Azacitidine Maintenance Therapy Postallogeneic Stem Cell Transplantation In Poorrisk Acute Myeloid Leukemia,
2023
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, OK 73104, USA
Azacitidine Maintenance Therapy Postallogeneic Stem Cell Transplantation In Poorrisk Acute Myeloid Leukemia, Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine is safe for post-transplant maintenance therapy in AML. Methods: We performed a single institutional prospective cohort study to evaluate the benefit of azacitidine maintenance therapy following allogeneic HSCT in poor-risk AML. The main objective of this study is to generate a hypothesis aiming to optimize post-transplantation outcomes in poor-risk AML. Forty-nine adults with poor-risk AML who underwent allogeneic HSCT were evaluated in a nonrandomized prospective cohort fashion. Thirty-one participants received …
Current Practice Of Oral Care For Hematopoietic Stem Cell Transplant Patients: A Survey Of The Eastern Mediterranean Blood And Marrow Transplantation Group,
2023
Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
Current Practice Of Oral Care For Hematopoietic Stem Cell Transplant Patients: A Survey Of The Eastern Mediterranean Blood And Marrow Transplantation Group, Hani Mawardi, Nathaniel Treister, Osama Felemban, Waleed Alamoudi, Ghada Algohary, Abdulrahman Alsultan, Nawal Alshehri, Illias Tazi, Marwan Shaheen, Mohamed Alsharani, Salem Alshemmari, Mutlu Arat, Mohamed Amine Bekadja, Murtadha Al-Khabori, Samar Okaily, Natasha Ali, Husam Abujazar, Wasil Jastaniah, Amir Ali Hamidieh, Sharukh Hashmi, Mahmoud Aljurf
Hematology/Oncology and Stem Cell Therapy
Introduction: The oral cavity is one of the most common sites impacted by hematopoietic stem cell transplantation (HSCT) with acute complications including mucositis, bleeding, salivary gland dysfunction, infection, and taste alteration. These complications may result in significant morbidity and can negatively impact outcomes such as length of stay and overall costs. As such, oral care during HSCT for prevention and management of oral toxicities is a standard component of transplant protocols at all centers. The objective of this study was to evaluate the current oral care practices for patients during HSCT at different transplant centers within the Eastern Mediterranean region. …
Outcomes Of Patients With Thrombocytopenia Evaluated At Hematology Subspecialty Clinics,
2023
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA
Outcomes Of Patients With Thrombocytopenia Evaluated At Hematology Subspecialty Clinics, Zaid H. Abdel Rahman, Kevin C. Miller, Hiba Jabbour, Yaser Alkhatib, Vijaya Donthireddy
Hematology/Oncology and Stem Cell Therapy
Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a common reason for hematology referrals. Workup for thrombocytopenia is not standardized and frequently does not follow an evidence-based algorithm. We conducted a systematic analysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytopenia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases …
Therapeutic Roles Of Antibody Drug Conjugates (Adcs) In Relapsed/Refractory Lymphomas,
2023
Division of Hematology/Oncology, Medical University of South Carolina, United States
Therapeutic Roles Of Antibody Drug Conjugates (Adcs) In Relapsed/Refractory Lymphomas, Hamza Hashmi, Alicia Darwin, Taiga Nishihori
Hematology/Oncology and Stem Cell Therapy
Relapsed or refractory lymphoma is commonly treated with combination chemoimmunotherapy and cellular immunotherapy. Modest response rates and associated toxicities are obstacles to achieving durable remission using traditional cytotoxic chemotherapy, especially in frail patients with advanced disease. Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. Several of these agents, which offer improved targeting, greater potency, and better therapeutic index over traditional chemotherapy, are changing the treatment landscape for lymphomas and other hematological malignancies. Despite the therapeutic potential of these agents, the delivery and release of cytotoxic agents …
